Skip to main content

Tricuspid Regurgitation (TR)

0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
2 programs
TTVI with LuX-Valve Plus SystemN/A1 trial
Transcatheter Tricuspid Valve InterventionN/A1 trial
Active Trials
NCT07454980Not Yet Recruiting680Est. Dec 2038
NCT06568003Active Not Recruiting15Est. Oct 2030
Abbott
AbbottABBOTT PARK, IL
1 program
Impact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal FunctionN/A1 trial
Active Trials
NCT06902922Not Yet Recruiting150Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
2031
Innovation PharmaceuticalsTTVI with LuX-Valve Plus System
AbbottImpact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal Function
Innovation PharmaceuticalsTranscatheter Tricuspid Valve Intervention

Clinical Trials (3)

Total enrollment: 845 patients across 3 trials

NCT07454980Innovation PharmaceuticalsTTVI with LuX-Valve Plus System

Pivotal Trial to Evaluate TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (The TRINITY Pivotal Trial)

Start: May 2026Est. completion: Dec 2038680 patients
N/ANot Yet Recruiting
NCT06902922AbbottImpact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal Function

Impact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal Function

Start: Mar 2025Est. completion: Sep 2027150 patients
N/ANot Yet Recruiting
NCT06568003Innovation PharmaceuticalsTranscatheter Tricuspid Valve Intervention

TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)

Start: Sep 2024Est. completion: Oct 203015 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.